IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small Cell Lung Cancer Cells

Benzer Materyaller

• Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Non–Small Cell Lung Cancer Cells
  Yazar:: Gao, Wen, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells
  Yazar:: Liu, Xiaoying, ve diğerleri
  Baskı/Yayın Bilgisi: (2012)
• RNAi-induced synthetic lethality in cancer therapy
  Yazar:: Dai, Bingbing, ve diğerleri
  Baskı/Yayın Bilgisi: (2009)
• Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo
  Yazar:: Meng, Jieru, ve diğerleri
  Baskı/Yayın Bilgisi: (2010)
• Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo.
  Yazar:: Jieru Meng, ve diğerleri
  Baskı/Yayın Bilgisi: (2010-11-01)